Self-reported cocaine use is not associated with elevations in high-sensitivity troponin I

Abstract

Objective: High-sensitivity troponin (hsTn) assays detect 10 times lower concentrations of cardiac troponin than conventional assays. We examined the effects of self-reported cocaine use to determine whether those with acute cocaine use being evaluated for ACS are more likely to have elevated hsTnI than those nonusers being evaluated for ACS.

Methods: We conducted a sub-analysis of a prospective cohort of ED patients evaluated for acute coronary syndrome. Recent cocaine use was determined by structured patient interviews. High-sensitivity troponin (Abbott) and conventional troponin I (Abbott, cTnI) were measured on samples drawn at presentation. Urine toxicology screen for cocaine metabolite was obtained at the discretion of treating clinicians.

Results: Of 1862 patients enrolled, 444 reported prior cocaine use and 99 reported cocaine use within the preceding month. Median hsTn in patients with last cocaine use within 24 h, 2–7 days, 1 week–1 month, >1 month, and no prior cocaine use were: 9 (IQR: 3–17) ng/L, 6 (IQR: 3–24.3) ng/L, 6 (IQR: 3–89.5) ng/L, 3 (IQR: 3–18.5) ng/L and 3 (IQR: 3–17) ng/L, respectively. Urine toxicology assays (UTox) for cocaine were performed in 640 (34.4%) patients. The median hsTn for those who were UTox+, UTox − and those without a UTox were: 9 ng/L (IQR: 3–48.5), 9 ng/L (IQR: 3–40) and 3 ng/L (IQR: 3–12), respectively. There were no differences in the prevalence of new troponin elevations (hsTn >99th percentile but cTnI <99th percentile) in those with recent cocaine use compared to those without recent cocaine use.

Conclusions: In this first investigation of hsTn in patients with self-reported recent cocaine use, we have determined that hsTn does not lead to an increase in the prevalence of troponin elevation in cocaine users.

Keywords:

• Cocaine toxicity
• cocaine cardiotoxicty
• cocaine MI

Disclosure statement

The original cohort study was funded by Abbott Laboratories. Abbott Laboratories also provided reagents for the study. Dr Frederick Korley, M.D., Ph.D. is supported by the Harold Amos Medical Faculty Development Award from the Robert Wood Johnson Foundation.